AstraZeneca’s Oral Anticoagulant AZD0837 Phase III Program Pushed Back To 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Backup compound to AstraZeneca’s failed Exanta is being investigated for a stability limitation; Crestor is the only branded statin to increase U.S. market share during 2008.